Literature DB >> 22364967

Thoracic or thoracoabdominal approaches to endovascular device removal and open aortic repair.

Scott A LeMaire1, Susan Y Green, Jae Hyun Kim, Aryan Sameri, Jennifer L Parenti, Peter H Lin, Joseph Huh, Joseph S Coselli.   

Abstract

BACKGROUND: Endovascular aortic repair is becoming increasingly common and diverse in its application despite ongoing uncertainty about long-term durability. Recent reports detail late conversion to open surgical repair to treat disease progression and repair failure. We describe our experience with using thoracic or thoracoabdominal approaches to endovascular device removal and open aortic repair after previous endovascular procedures.
METHODS: Thirty-five patients underwent open aortic repair through thoracotomy (n=7) or thoracoabdominal incision (n=28) 0.5 to 48 months after undergoing endovascular thoracic (n=27) or abdominal (n=8) aortic procedures. Indications for open repair included expanding aneurysm (n=23), device infection (n=8), fistula (n=5), pseudoaneurysm (n=2), aneurysm rupture (n=2), and restenosis (n=1). Endovascular devices were completely removed in 26 patients and partially removed in 9. Descending thoracic aortic repair was performed in 10 patients, thoracoabdominal aortic repair in 24, and juxtarenal abdominal aortic repair in 1.
RESULTS: There were 2 in-hospital deaths (6%), both in patients who presented with endovascular device infection. There were 8 late deaths. Overall 1-year survival was 83%±7%. Among the patients who presented with infected devices, 3 experienced major late complications, including persistent infection, pseudoaneurysm, and recurrent fistula; 2 of these patients succumbed to late deaths.
CONCLUSIONS: Open surgical repair after previous endovascular aortic procedures is successful in the majority of patients, particularly in those without device infections. Achieving definitive aortic repair in patients with infected endovascular devices is particularly challenging.
Copyright © 2012 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22364967     DOI: 10.1016/j.athoracsur.2011.10.080

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  8 in total

1.  When stent-grafts fail: extraction and open surgical repair of the thoracic aorta.

Authors:  Joseph S Coselli; Susan Y Green; Scott A LeMaire
Journal:  Tex Heart Inst J       Date:  2011

Review 2.  Update on repairs of the thoracoabdominal aorta.

Authors:  Joseph S Coselli
Journal:  Tex Heart Inst J       Date:  2013

3.  Type B aortic dissection triggered by heart transplantation in a patient with Marfan syndrome.

Authors:  Tjorven Audenaert; Michel De Pauw; Katrien François; Julie De Backer
Journal:  BMJ Case Rep       Date:  2015-10-16

Review 4.  Open aortic surgery after thoracic endovascular aortic repair.

Authors:  Joseph S Coselli; Konstantinos Spiliotopoulos; Ourania Preventza; Kim I de la Cruz; Hiruni Amarasekara; Susan Y Green
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-06-17

Review 5.  Hybrid thoracoabdominal aortic aneurysm repair: is the future here?

Authors:  Vicente Orozco-Sevilla; Scott A Weldon; Joseph S Coselli
Journal:  J Vis Surg       Date:  2018-03-30

6.  Explantation of infected thoracic endovascular aortic repair.

Authors:  Emily Y Fan; Dejah R Judelson; Andres Schanzer
Journal:  J Vasc Surg Cases Innov Tech       Date:  2018-12-04

Review 7.  Secondary Open Aortic Procedure Following Thoracic Endovascular Aortic Repair: Meta-Analytic State of the Art.

Authors:  Ivancarmine Gambardella; George A Antoniou; Francesco Torella; Cristiano Spadaccio; Aung Y Oo; Mario Gaudino; Francesco Nappi; Matthew A Shaw; Leonard N Girardi
Journal:  J Am Heart Assoc       Date:  2017-09-13       Impact factor: 5.501

8.  Total Aortic Arch Replacement after Thoracic Endovascular Aortic Repair Using Left Subclavian Arterial Perfusion.

Authors:  Taijiro Sueda; Shinya Takahashi; Keijiro Katayama
Journal:  Ann Thorac Cardiovasc Surg       Date:  2018-04-26       Impact factor: 1.520

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.